Tags : Worldwide

Pharma

Cerecor Signs a Worldwide License Agreement with Kyowa Kirin for

Shots: Kyowa Kirin to receive up front, regulatory & commercial milestones along with royalties and a share of sublicensing income. The company also has an option to retain rights in Japan Cerecor to get exclusive rights for the development, manufacturing and commercialization of CERC-00 for all indications globally including the US, EU and Japan The […]Read More

Pharma

Merck KGaA Signs an Exclusive Worldwide License Agreement with Day

Shots: Merck KGaA to receive up front, additional regulatory, approval, and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors Day One plans to initiate a P-I/II study to evaluate the safety, tolerability, and preliminary efficacy […]Read More

Pharma

Onward Signs a Worldwide Exclusive License and Co-Development Agreement with

Shots: Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies Onward get the right to pursue development, manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early clinical program Biomunex is responsible for early preclinical development, while […]Read More

Pharma

Bayer Signs an Exclusive Worldwide License Agreement with Atara for

Shots: Atara to receive $60M upfront and ~$610M as development, regulatory & commercialization milestones + tiered royalties on net sales. The collaboration focuses on off-the-shelf T-cell immunotherapy ATA3271 and ATA2271 Atara will lead to IND and process development for ATA3271 and will continue to be responsible for P-I study of ATA2271 while Bayer will be […]Read More

Pharma

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics

Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002 BMS will be responsible for the development & […]Read More

Biotech

Sarepta Signs an Exclusive Worldwide License with Hansa to Develop

Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy sales that arises from treating Ab-positive patients enabled through imlifidase pre-treatment Sarepta get an exclusive WW license to develop and promote imlifidase as a pre-treatment […]Read More

Pharma

AbbVie Signs an Exclusive Worldwide Option and License Agreement with

Shots: Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales of ALPN-101 AbbVie to get an option to exclusively license ALPN-101, following exercising the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for ALPN-101 During the option period, […]Read More

Pharma

AstraZeneca Signs Exclusive Worldwide License Agreement with Accent for RMP-Targeting

Shots: Accent to receive $55M upfront and $1.1B as co-development option and milestone payment, plus royalties and profit split based on the option to co-develop and co-commercialize RMP-targeting therapies for the treatment of cancer in the US  Accent will be responsible for research and development activities for a nominated preclinical program through to the end […]Read More